Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zonegran Postmarketing Skin/Renal AEs To Be Considered Unlabeled Events

Executive Summary

Elan should consider any postmarketing reports of allergic, skin, blood disorder and renal reactions with its new antiepileptic Zonegran to be unlabeled events, FDA told the company.

You may also be interested in...



Zonegran Label Revision Recommends Monitoring For Decreased Sweating

Patients on Elan's anticonvulsant Zonegran should be closely monitored for decreased sweating and increased body temperature, the company said in a "Dear Doctor" letter

Zonegran Label Revision Recommends Monitoring For Decreased Sweating

Patients on Elan's anticonvulsant Zonegran should be closely monitored for decreased sweating and increased body temperature, the company said in a "Dear Doctor" letter

Novartis Trileptal Has Fewer Hemopoietic, Dermatologic AEs Than Tegretol

Novartis' Trileptal labeling indicates that the anticonvulsant may be associated with fewer serious hemopoietic and dermatologic adverse events than the company's older antiseizure drug Tegretol.

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel